PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Nadroparin→

Nadroparin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
~4300 g/mol
Drug class
Low-molecular-weight heparin (LMWH)antithrombin-dependent anticoagulant
Mechanism of action
Binds antithrombin and accelerates inhibition of coagulation factor Xa, with less activity against thrombin (factor IIa) than unfractionated heparin. This reduces fibrin formation and thrombus propagation.
Indications / reported uses
  • Prevention of venous thromboembolism in surgical and medical patients at risk
  • Treatment of deep-vein thrombosis and selected thromboembolic conditions, and use in unstable angina or non-Q-wave myocardial infarction where authorised; product indications vary by jurisdiction

Sources: NLM MeSH — Nadroparin · PubMed — Nadroparin clinical pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Nadroparin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Nadroparin Permitted Daily Exposure (PDE) report (the Nadroparin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Nadroparin Occupational Exposure Limit (OEL) report (the Nadroparin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.